|Articles|June 1, 2001

Meeting and event spending increased in 2000

Pharmaceutical meetings and events continue to grow as integral elements in overall promotion of prescription drugs, according to Newtown, PA-based Scott-Levin's "Physician Meeting & Event Audit," a survey of more than 3,400 doctors. The survey found that pharmaceutical companies spent $1.9 billion on events for physicians in 2000, 14% more than in 1999.

Pharmaceutical meetings and events continue to grow as integral elements in overall promotion of prescription drugs, according to Newtown, PA-based Scott-Levin's "Physician Meeting & Event Audit," a survey of more than 3,400 doctors. The survey found that pharmaceutical companies spent $1.9 billion on events for physicians in 2000, 14% more than in 1999.

By comparison, the industry spent the same amount on direct-to-consumer ads for prescription products between January and September 2000.

The survey also found that pharmaceutical companies devoted an average of 17% of their promotional budgets to meetings and events, about the same proportion as in 1999. Total promotional spending for prescription drugs rose from $9 billion to $10.4 billion in 2000.

Scott-Levin projects that 314,022 physician events were held in 2000, an increase of about 11%. Event activity almost doubled between 1996 and 2000. PR


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.